Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 8.650-9.000 for the period, compared to the consensus earnings per share estimate of 8.020. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Analyst Ratings Changes

A number of research firms have commented on HALO. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 31st. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $2.17 during mid-day trading on Thursday, reaching $85.76. The stock had a trading volume of 2,679,037 shares, compared to its average volume of 1,795,718. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $86.00. The firm has a market cap of $10.17 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 0.34 and a beta of 0.85. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The business’s fifty day moving average is $75.39 and its 200-day moving average is $71.15.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts forecast that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the sale, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock worth $5,102,643 in the last three months. Company insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voloridge Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at $77,587,000. Qube Research & Technologies Ltd purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $51,295,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the period. Royal London Asset Management Ltd. increased its position in Halozyme Therapeutics by 122.3% during the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock worth $57,321,000 after purchasing an additional 606,236 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Halozyme Therapeutics by 155.7% during the third quarter. AQR Capital Management LLC now owns 968,511 shares of the biopharmaceutical company’s stock worth $71,031,000 after purchasing an additional 589,711 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.